Brand Name: AutoPulse NXT Resuscitation System Product Name: AutoPulse NXT Platform Model/Catal...
FDA Device Recall #Z-1533-2025 — Class I — March 4, 2025
Recall Summary
| Recall Number | Z-1533-2025 |
| Classification | Class I — Serious risk |
| Date Initiated | March 4, 2025 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | ZOLL Circulation, Inc. |
| Location | San Jose, CA |
| Product Type | Devices |
| Quantity | 91 |
Product Description
Brand Name: AutoPulse NXT Resuscitation System Product Name: AutoPulse NXT Platform Model/Catalog Number: Model 200 (Catalog Number: 8700-001070-1) Software Version: Version 2.0.1 Product Description: The AutoPulse Resuscitation System Model 200 is an automated, portable, battery powered device that compresses the chest of an adult human as an adjunct to manual CPR. Component: N/A
Reason for Recall
AutoPulse NXT Resuscitation System may not provide adequate chest compressions or may stop compressions due to code FC1060.
Distribution Pattern
US: AL, CA, CT, FL, IL, KS, LA, MN, MO, MT, NC, ND, NM, NY, OH, OK< PA, TX, WI OUS: Canada, Hong Kong,
Lot / Code Information
UDI: (01) 00849111003384/Serial number: 1179 1168 1178 1184 1188 1197 1109 1110 1126 1166 1169 1152 1199 1202 1111 1185 1198 1203 1206 1208 1211 1212 1172 1182 1130 1128 1129 1189 1183 1131 1134 1191 1186 1192 1170 1173 1175 1180 1174 1176 1187 1177 1116 1165 1118 1119 1193 1138 1139 1145 1146 1147 1148 1149 1150 1153 1155 1159 1161 1162 1163 1164 1181 1141 1108 1190 1195 1120 1121 1122 1123 1107 1112 1113 1114 1115 1137 1140 1196
Other Recalls from ZOLL Circulation, Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| Z-0118-2023 | Class II | AutoPulse Li-ion Battery used on the AutoPulse ... | Sep 22, 2022 |
| Z-0043-2022 | Class II | ZOLL, REF 8700-0793-40 (SL-2593AE) SOLEX 7, Int... | Aug 6, 2021 |
| Z-0046-2022 | Class II | ZOLL, REF 8700-0787-40 (IC-3893AE), ICY Intrava... | Aug 6, 2021 |
| Z-0057-2022 | Class II | Zoll, REF 8700-0657-40 (IC-3893AE), ICY Intrava... | Aug 6, 2021 |
| Z-0056-2022 | Class II | Zoll, REF 8700-0695-40 (IC-3893AE), ICY Intrava... | Aug 6, 2021 |
Frequently Asked Questions
Contact your healthcare provider and the device manufacturer immediately. Check whether your specific model number and lot number are included in the recall scope. For external devices, stop using the affected product and arrange a replacement. For implanted devices, do not panic — removal is typically not required unless the risk assessment clearly indicates it. Your physician will guide you based on your individual clinical situation and the FDA's recommended actions. Report any adverse effects you may have experienced to FDA MedWatch at 1-800-FDA-1088.
Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.
Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.
What Should You Do?
Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.